Neuronetics Inc (STIM)

$3.49

-0.03

(-0.85%)▲

Market is closed - opens 7 PM, 29 Apr 2024

Insights on Neuronetics Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 15.54M → 20.31M (in $), with an average increase of 8.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -9.39M → -5.37M (in $), with an average increase of 74.7% per quarter

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 0.2% return, outperforming this stock by 70.2%

Performance

  • $3.35
    $3.53
    $3.49
    downward going graph

    4.15%

    Downside

    Day's Volatility :5.24%

    Upside

    1.13%

    downward going graph
  • $1.03
    $5.07
    $3.49
    downward going graph

    70.49%

    Downside

    52 Weeks Volatility :79.68%

    Upside

    31.16%

    downward going graph

Returns

PeriodNeuronetics IncSector (Health Care)Index (Russel 2000)
3 Months
5.07%
0.5%
0.0%
6 Months
235.24%
11.7%
0.0%
1 Year
57.85%
6.2%
2.2%
3 Years
-69.99%
13.5%
-23.0%

Highlights

Market Capitalization
112.4M
Book Value
$1.18
Earnings Per Share (EPS)
-1.05
Wall Street Target Price
7.0
Profit Margin
-42.31%
Operating Margin TTM
-11.95%
Return On Assets TTM
-15.34%
Return On Equity TTM
-66.17%
Revenue TTM
71.3M
Revenue Per Share TTM
2.49
Quarterly Revenue Growth YOY
11.600000000000001%
Gross Profit TTM
49.7M
EBITDA
-26.5M
Diluted Eps TTM
-1.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.92
EPS Estimate Next Year
-0.64
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Neuronetics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 100.57%

Current $3.49
Target $7.00

Company Financials

FY18Y/Y Change
Revenue
52.8M
↑ 30.53%
Net Income
-24.1M
↑ 50.05%
Net Profit Margin
-45.66%
↓ 5.94%
FY19Y/Y Change
Revenue
62.7M
↑ 18.72%
Net Income
-34.3M
↑ 42.34%
Net Profit Margin
-54.74%
↓ 9.08%
FY20Y/Y Change
Revenue
49.2M
↓ 21.41%
Net Income
-32.3M
↓ 5.9%
Net Profit Margin
-65.55%
↓ 10.81%
FY21Y/Y Change
Revenue
55.3M
↑ 12.32%
Net Income
-35.6M
↑ 10.3%
Net Profit Margin
-64.37%
↑ 1.18%
FY22Y/Y Change
Revenue
65.2M
↑ 17.89%
Net Income
-39.2M
↑ 10.13%
Net Profit Margin
-60.13%
↑ 4.24%
FY23Y/Y Change
Revenue
71.3M
↑ 9.42%
Net Income
-30.2M
↓ 23.0%
Net Profit Margin
-42.31%
↑ 17.82%
Q3 FY22Q/Q Change
Revenue
16.5M
↑ 1.03%
Net Income
-7.8M
↓ 29.72%
Net Profit Margin
-47.06%
↑ 20.6%
Q4 FY22Q/Q Change
Revenue
18.2M
↑ 10.3%
Net Income
-8.9M
↑ 14.0%
Net Profit Margin
-48.64%
↓ 1.58%
Q1 FY23Q/Q Change
Revenue
15.5M
↓ 14.61%
Net Income
-11.1M
↑ 25.78%
Net Profit Margin
-71.64%
↓ 23.0%
Q2 FY23Q/Q Change
Revenue
17.6M
↑ 13.32%
Net Income
-4.9M
↓ 55.98%
Net Profit Margin
-27.83%
↑ 43.81%
Q3 FY23Q/Q Change
Revenue
17.9M
↑ 1.56%
Net Income
-9.4M
↑ 91.61%
Net Profit Margin
-52.51%
↓ 24.68%
Q4 FY23Q/Q Change
Revenue
20.3M
↑ 13.59%
Net Income
-5.4M
↓ 42.74%
Net Profit Margin
-26.47%
↑ 26.04%
FY18Y/Y Change
Total Assets
117.0M
↑ 200.53%
Total Liabilities
46.0M
↓ 80.15%
FY19Y/Y Change
Total Assets
100.2M
↓ 14.4%
Total Liabilities
52.3M
↑ 13.78%
FY20Y/Y Change
Total Assets
78.7M
↓ 21.47%
Total Liabilities
53.2M
↑ 1.62%
FY21Y/Y Change
Total Assets
141.2M
↑ 79.54%
Total Liabilities
56.0M
↑ 5.42%
FY22Y/Y Change
Total Assets
116.9M
↓ 17.23%
Total Liabilities
59.8M
↑ 6.74%
FY23Y/Y Change
Total Assets
115.8M
↓ 0.9%
Total Liabilities
81.6M
↑ 36.47%
Q3 FY22Q/Q Change
Total Assets
119.2M
↓ 3.02%
Total Liabilities
56.2M
↑ 3.14%
Q4 FY22Q/Q Change
Total Assets
116.9M
↓ 1.97%
Total Liabilities
59.8M
↑ 6.37%
Q1 FY23Q/Q Change
Total Assets
103.6M
↓ 11.36%
Total Liabilities
55.3M
↓ 7.63%
Q2 FY23Q/Q Change
Total Assets
100.4M
↓ 3.1%
Total Liabilities
54.9M
↓ 0.62%
Q3 FY23Q/Q Change
Total Assets
93.0M
↓ 7.38%
Total Liabilities
55.0M
↑ 0.24%
Q4 FY23Q/Q Change
Total Assets
115.8M
↑ 24.57%
Total Liabilities
81.6M
↑ 48.31%
FY18Y/Y Change
Operating Cash Flow
-20.6M
↑ 84.77%
Investing Cash Flow
-1.0M
↑ 70.2%
Financing Cash Flow
97.0M
↑ 306.95%
FY19Y/Y Change
Operating Cash Flow
-30.5M
↑ 48.04%
Investing Cash Flow
-813.0K
↓ 19.58%
Financing Cash Flow
2.4M
↓ 97.51%
FY20Y/Y Change
Operating Cash Flow
-28.4M
↓ 6.86%
Investing Cash Flow
-730.0K
↓ 10.21%
Financing Cash Flow
2.4M
↓ 2.11%
FY21Y/Y Change
Operating Cash Flow
-28.0M
↓ 1.43%
Investing Cash Flow
-9.8M
↑ 1247.81%
Financing Cash Flow
83.0M
↑ 3403.84%
FY22Y/Y Change
Operating Cash Flow
-30.7M
↑ 9.85%
Investing Cash Flow
6.7M
↓ 168.41%
Financing Cash Flow
207.0K
↓ 99.75%
Q3 FY22Q/Q Change
Operating Cash Flow
-6.5M
↓ 27.3%
Investing Cash Flow
9.3M
↓ 1060.04%
Financing Cash Flow
245.0K
↑ 2350.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.1M
↓ 52.36%
Investing Cash Flow
-503.0K
↓ 105.42%
Financing Cash Flow
245.0K
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.0M
↑ 190.84%
Investing Cash Flow
-183.0K
↓ 63.62%
Financing Cash Flow
499.0K
↑ 103.67%
Q2 FY23Q/Q Change
Operating Cash Flow
-15.0M
↑ 66.71%
Investing Cash Flow
-642.0K
↑ 250.82%
Financing Cash Flow
-62.0K
↓ 112.42%

Technicals Summary

Sell

Neutral

Buy

Neuronetics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Neuronetics Inc
Neuronetics Inc
-26.05%
235.24%
57.85%
-69.99%
-79.33%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-7.79%
23.1%
1.62%
-12.39%
110.45%
Agilent Technologies Inc.
Agilent Technologies Inc.
-5.57%
30.74%
2.44%
-0.71%
76.14%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
0.51%
29.89%
7.24%
15.73%
109.26%
Danaher Corp.
Danaher Corp.
-1.07%
26.91%
5.73%
-4.77%
87.73%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-5.55%
26.87%
23.16%
0.24%
68.7%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Neuronetics Inc
Neuronetics Inc
NA
NA
NA
-0.92
-0.66
-0.15
NA
1.18
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
49.03
49.03
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
32.89
32.89
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.35
37.35
2.81
21.53
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
45.86
45.86
3.13
7.63
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.05
32.05
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Neuronetics Inc
Neuronetics Inc
Buy
$112.4M
-79.33%
NA
-42.31%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.1B
110.45%
49.03
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$40.8B
76.14%
32.89
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$220.4B
109.26%
37.35
13.99%
Danaher Corp.
Danaher Corp.
Buy
$185.5B
87.73%
45.86
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.6B
68.7%
32.05
9.06%

Institutional Holdings

  • Cannell Capital LLC

    9.31%

  • Archon Capital Management LLC

    8.53%

  • Balyasny Asset Management LLC

    4.76%

  • Vanguard Group Inc

    4.55%

  • Silvercrest Asset Management Group LLC

    3.79%

  • Kent Lake Capital LLC

    3.75%

Corporate Announcements

  • Neuronetics Inc Earnings

    Neuronetics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.

Organization
Neuronetics Inc
Employees
203
CEO
Mr. Keith J. Sullivan
Industry
Health Technology

Discover More

FAQs